Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization

DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced the closing of a registered direct offering with a U.S.-based private investment firm, priced at a premium to the Company’s recent closing share price. Management believes the transaction reflects investor interest in the Company’s strategy and long-term opportunities.

The financing follows the Company’s October 1, 2026 announcement that its subsidiary, MangoRx IP Holdings, LLC ("MangoRx IP"), entered into agreements for $2.5 million in aggregate strategic investment commitments in exchange for a 25% membership interest in its subsidiary. MangoRx IP has received $1.75 million of the committed capital, with the remaining $750,000 due by November 28, 2026, subject to the applicable agreement. This subsidiary-level investment did not require the issuance of Mangoceuticals common stock or other parent-company securities. The proceeds are intended to advance the commercialization of MangoRx IP’s intellectual property portfolio.

Together, the transactions provide capital at both the parent and subsidiary levels through distinct structures. The registered direct offering provides additional working capital to Mangoceuticals, while the subsidiary financing is intended to support intellectual property commercialization without directly diluting the publicly traded parent’s common stock through a securities issuance.